ID   JHOC-8
AC   CVCL_4642
SY   JHOC8
DR   CLO; CLO_0051446
DR   BioSample; SAMN03472070
DR   cancercelllines; CVCL_4642
DR   Cosmic; 2582798
DR   RCB; RCB1723
DR   Wikidata; Q54898651
RX   PubMed=25846456;
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg479Gln (c.1436G>A); ClinVar=VCV000376419; Zygosity=Unspecified (PubMed=25846456).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25846456).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): RCB=RCB1723
ST   Amelogenin: X
ST   CSF1PO: 14
ST   D13S317: 8
ST   D16S539: 9
ST   D5S818: 11
ST   D7S820: 8,11
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 14,17
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 19
//
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).
//